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Abstract
Background: In normal and neoplastic cells, growth-promoting, proangiogenic, cytotoxic and pro-apoptotic effects
have all been attributed to cathelicidin antimicrobial peptide (CAMP). Nevertheless, little is known about the factors
regulating this peptide expression in breast cancer. Herein we asked if the well-known antineoplastic hormone
calcitriol could differentially modulate CAMP gene expression in human breast cancer cells depending on the cell
phenotype in terms of efficacy and potency.
Methods: The established breast cancer cell lines MCF7, BT-474, HCC1806, HCC1937, SUM-229PE and a primary cell
culture generated from invasive ductal breast carcinoma were used in this study. Calcitriol regulation of cathelicidin
gene expression in vitro and in human breast cancer xenografts was studied by real time PCR. Tumorigenicity was
evaluated for each cell line in athymic mice.
Results: Estrogen receptor (ER)α + breast cancer cells showed the highest basal CAMP gene expression. When incubated
with calcitriol, CAMP gene expression was stimulated in a dose-dependent and cell phenotype-independent manner.
Efficacy of calcitriol was lower in ERα + cells when compared to ERα- cells (<10 vs. >70 folds over control, respectively).
Conversely, calcitriol lowest potency upon CAMP gene expression was observed in the ERα-/EGFR+ SUM-229PE cell line
(EC50 = 70.8 nM), while the highest was in the basal-type/triple-negative cells HCC1806 (EC50 = 2.13 nM) followed by
ERα + cells MCF7 and BT-474 (EC50 = 4.42 nM and 14.6 nM, respectively). In vivo, lower basal CAMP gene expression was
related to increased tumorigenicity and lack of ERα expression. Xenografted triple-negative breast tumors of
calcitriol-treated mice showed increased CAMP gene expression compared to vehicle-treated animals.
Conclusions: Independently of the cell phenotype, calcitriol provoked a concentration-dependent stimulation on
CAMP gene expression, showing greater potency in the triple negative HCC1806 cell line. Efficacy of calcitriol was
lower in ERα + cells when compared to ERα- cells in terms of stimulating CAMP gene expression. Lower basal
CAMP and lack of ERα gene expression was related to increased tumorigenicity. Our results suggest that calcitriol
anti-cancer therapy is more likely to induce higher levels of CAMP in ERα- breast cancer cells, when compared to
ERα + breast cancer cells.
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Background
Paradoxical effects have been described for cathelicidin
(CAMP) in cancer biology. Some studies have shown cyto-
toxic, antiproliferative and pro-apoptotic effects [1–4],
whereas others reported growth-promoting, proangiogenic,
prometastatic and invasive-inductive effects of CAMP in
different malignant-type cells [5–8]. These effects are the
result of tissue-specific signaling pathways triggered by
CAMP in an intra- or extra-cellular manner [9] involving
several growth factor receptors [10–12] and/or toll-like re-
ceptors [13]. In fact, CAMP overexpression has been
shown to suppress tumorigenesis in colon and gastric can-
cer but also to promote development and progression of
ovarian, lung and breast cancer [9]. Of note, CAMP signali-
zation may activate signaling cascades potentially involved
in carcinogenesis, such as those involving mitogen acti-
vated kinases, protein kinase C or nuclear factor kappa B.
Therefore, overexpression of CAMP is generally associated
with tumor promotion activity, in a concentration and/or
tissue specific fashion. Particularly in the breast, CAMP is
abundantly produced in both normal and malignant condi-
tions, while its maximum expression has been found
among high-grade breast tumors [5]. Interestingly, CAMP
expression is closely correlated with that of epidermal
growth factor receptor 2 (HER2) and with the presence of
lymph node metastases in estrogen receptor (ER) + breast
tumors, suggesting a prometastatic role for CAMP in
breast malignancy [14]. The regulatory factors acting upon
CAMP are not yet completely understood. Normally, the
expression of CAMP is induced in response to injury or
bacterial challenge, resulting in its accumulation in the site
of distress. Indeed, inflammatory mediators may induce
CAMP in some settings [15]; however, this is not always
the case, as seen in tumor necrosis factor-α treated tro-
phoblasts and other cell types, where CAMP was either
not regulated or downregulated by inflammatory cyto-
kines [16, 17]. In humans, there is evidence that the most
robust CAMP inducer is calcitriol, the vitamin D more ac-
tive metabolite. This hormone, acting through its nuclear
receptor (VDR), transcriptionally induces robust expres-
sion of CAMP by acting through a vitamin D response
element located in its promoter [18]. Calcitriol is well
known for its anticancer properties, which are being stud-
ied in preclinical and clinical settings. Given the potential
pharmacological use of calcitriol for therapeutic purposes
in breast cancer patients, herein we thought of importance
to investigate the regulatory actions of this hormone upon
CAMP gene expression under in vitro and in vivo condi-
tions using different phenotypes of breast cancer cells.
Methods
Breast cancer cell cultures
The established human breast cancer cell lines MCF7,
BT-474, HCC1806, HCC1937 (ATCC, Manassas, VA),
SUM-229PE (Asterand, San Francisco, CA), and a pri-
mary cell culture generated from invasive ductal breast
carcinoma (IDC) [19], were maintained under standard
cell culture conditions. For experiments, cells were incu-
bated in the presence of different calcitriol concentra-
tions (0.1–1000 nM, Sigma-Aldrich, St Louis, MO) or its
vehicle (0.1 % ethanol) during 24 h. Afterwards, cells
were used for RNA isolation. Characterization of the
cells was performed by immunocytochemistry in order to
analyze the expression of particular molecular markers.
Immunocytochemistry
Cultured cells were grown on glass coverslips and fix-
ated in 96 % ethanol. Antigen retrieval was done by
autoclaving in Retriever EDTA (Bio SB, Santa Bárbara
CA, USA). Slides were blocked with immunodetector
peroxidase blocker (Bio SB). The following primary anti-
bodies were incubated for 1 h: Anti- ERα (1:250, Bio SB),
anti-VDR (1:100, Santa Cruz Biotechnology Inc, CA,
USA), anti-HER2 (1:100, Cell Signaling Technology,
Beverly, MA) and anti-epidermal growth factor recep-
tor (EGFR, 1:100, Bio SB). After washing, the slides were
sequentially incubated with immuno-Detector Biotin-Link
and immuno-Detector HRP label (Bio SB) during 10 min
each. Staining was completed with diaminobenzidine
(DAB) and slides were counterstained with hematoxylin.
PCR amplifications
Calcitriol effects upon CAMP gene expression were
studied by extracting total RNA from treated cells and
resected tumors using Trizol reagent (Life Technologies,
CA, USA). The concentration of RNA was estimated
spectrophotometrically at 260/280 nm and a constant
amount of RNA (2 μg) was reverse transcribed using a
commercial assay (Roche Applied Science, IN, USA).
Gene expression of the housekeeping gene β-actin
(ACTB) was used as internal control. Primers sequences
were as follows: CAMP [GenBank:NM_004345.3]: for-
ward: tcg gat gct aac ctc tac cg, reverse: gtc tgg gtc ccc
atc cat and ACTB [GenBank:NM_001101.3]: forward: cca
aac cgc gag aag atg a, reverse: cca gag gcg tac agg gat ag.
Corresponding probe numbers from the universal probe
library (Roche) were: 85 and 64 for CAMP and ACTB,
respectively. Real time PCR amplifications were carried
on a LightCycler® 480 Instrument (Roche), according to
the following protocol: activation of Taq DNA polymer-
ase and DNA denaturation at 95 °C for 10 min, pro-
ceeded by 45 amplification cycles of 10 s at 95 °C, 30 s
at 60 °C, and 1 s at 72 °C.
The calcitriol concentration producing 50 % CAMP
gene expression stimulation (EC50) was calculated by
non-linear regression analysis using sigmoidal fitting
with a sigmoidal dose–response curve by means of the
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scientific graphing software Origin (OriginLab Corporation,
Northampton, MA, USA).
Induction of tumors in athymic mice
Athymic female BALB/c homozygous, inbred Crl:NU
(NCr)-Foxn1nu nude mice (~6 weeks of age) were kept in
ventilated cages with bedding of aspen wood-shavings,
controlled temperature, humidity and 12:12 light:dark
periods. Sterile water and feed (standard PMI 5053 feed)
were given ad libitum. Endpoints compatible with the
scientific objectives of this work were cautiously observed
preserving strict animal welfare standards. To evaluate the
physical status of each mouse, a scoring method was used
which included the following categories: 1) dehydration/
loss of appetite, 2) body weight, 3) natural behavior, 4)
provoked behavior and 5) inflammation/ulceration in in-
jection site. A value of 1–2 was assigned to the first cate-
gory while 1–3 was used for the last 4 categories. A total
score of 14 indicated wellbeing, while lower scores indi-
cated progressive health deterioration. A score < 9 was an
automatic endpoint. Tumorigenicity was evaluated for
each cell line used in this study by subcutaneous injection
of 2.0 × 106 cells in 0.1 mL of sterile saline solution into
the upper part of the posterior limb of each mouse.
Therapeutic protocol
When the tumors reached a palpable mass (~ 3 mm),
mice were separated in two groups: control and calcitriol-
treated (calcitriol Geldex, GELpharma, México, 12.5 μg/kg
of body weight i.p. in 100 μL once a week during 3 weeks).
IDC and HCC1806 cells were used to xenograft mice
(total mice = 22; 11 for each cell line). Body weights and
tumor sizes were measured thrice weekly throughout the
experiment. Tumor volume was calculated using the
standard formula (length x width2)/2, where length is the
largest dimension and width the smallest dimension per-
pendicular to the length. Tumors were measured with a
caliper always by the same person. Relative tumor volume
was calculated for each tumor by dividing the tumor vol-
ume on day 21 by that on day 0 (which corresponded to
the tumor volume in the first day of treatment, and was
set to one). After sacrifice, tumors were excised and proc-
essed for RNA extraction.
Statistical analysis
Statistical differences for in vitro dose-response assays
were determined by one-way ANOVA followed by ap-
propriate post-hoc tests using a specialized software
package (SigmaStat, Jandel Scientific). For in vivo com-
parisons between control and calcitriol-treated groups
Student’s t-test was used. Differences were considered
statistically significant at P < 0.05.
Results
Characterization of the cells used in this study
Expression of VDR, ERα, HER2 and EGFR for each cell
line is depicted in Table 1.
Also, the functionality of the VDR was corroborated
by the calcitriol-dependent induction of CYP24A1 gene
expression (Table 2).
Calcitriol induces CAMP gene expression in cultured
breast cancer cells of different phenotype, but more
strongly in ERα- cells
Differential basal CAMP gene expression was observed
depending on the cell line. In particular, ERα + breast
cancer cells showed the highest basal CAMP gene ex-
pression, while the lowest was obtained in ERα- cells
(Fig. 1). On the other hand, in all cell lines tested, a cal-
citriol dose-dependent stimulation of CAMP gene ex-
pression was observed (Fig. 2). In particular, in the
ERα-/EGFR+ cell line SUM-229PE, calcitriol, at the
highest concentration tested, showed the greatest effi-
cacy in terms of stimulating CAMP gene expression
(>200 folds over control). Meanwhile, in the basal-type/
triple-negative cell lines HCC1937 and HCC1806 calci-
triol increased CAMP gene expression by approximately
70–100 folds over the control. In contrast, ERα + cells
MCF7 and BT-474 responded more moderately to calcitriol
(<10 folds over control, Fig. 2). Based on the EC50 values,
the potency/sensibility of calcitriol upon CAMP gene ex-
pression was: HCC1806 >MCF7 > BT-474 >HCC1937 >
IDC > SUM-229PE (Table 3).
In a xenograft model of breast cancer, calcitriol induced
CAMP gene expression
We first tested tumorigenicity of all cancer cell lines in a
murine model. Under the conditions of this study, only
HCC1806 and IDC readily formed tumors. We observed
that lower basal CAMP gene expression and lack of ERα
positivity were cell features related to increased tumori-
genicity. Therefore, CAMP gene expression in vivo studies
were carried out in HCC1806 and IDC tumors. Consider-
ing the in vitro calculated potency of calcitriol upon
CAMP gene expression, which was higher in HCC1806
compared to IDC (2.13 nM vs. 17.1 nM, respectively), and
the greatest efficacy of calcitriol to induce its canonic
Table 1 Cell characterization by immunocytochemistry
MCF7 BT-474 SUM-229PE HCC1806 HCC1937 IDC
VDR + + + + + +
ERα + + – – – –
HER2 – + S – – –
EGFR – + + + + +
Expression of vitamin D receptor (VDR), estrogen receptor-α (ERα), epidermal
growth factor receptor (EGFR) and epidermal growth factor receptor 2 (HER2)
are depicted. S = Only slight expression was detected
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transcriptional target CYP24A1 in HCC1806 vs. IDC cells
(7579 vs. 47 folds over the control, respectively), the re-
sults observed in vivo mirrored in vitro findings. Indeed,
calcitriol treatment of mice xenografted with HCC1806
cells significantly stimulated tumoral CAMP gene ex-
pression compared to tumors from untreated mice. In
contrast, in IDC-grafted mice calcitriol did not signifi-
cantly affect tumoral CAMP gene expression (Fig. 3). In
both xenotransplanted mouse models calcitriol reduced,
although not significantly, the relative tumor volume
(Fig. 4).
Serum levels of total calcium and body weight in
calcitriol-treated xenotransplanted mice
Serum samples from each experimental group were
pooled. As expected, serum total calcium was higher in
calcitriol treated mice compared to controls (10.6 vs.
9.9 mg/dL); however, no signs of hypercalcemia were de-
tected (e.g. dehydration, weight loss). Final body weights
were not significantly different among the treated and
control groups.
Discussion
Cathelicidin is produced by the human mammary gland
and is found in human milk exerting antimicrobial activity
[20], which highlights the important physiological role of
this antimicrobial peptide in the newborn innate immune
defense during lactation. Nevertheless, in a pathological
scenario of the breast, cathelicidin effects are controversial
since it has been implicated in tumor-suppressive activities,
but also in promoting tumor growth and vascularization
[5, 8, 10, 21]. Given that calcitriol, a recognized antineo-
plastic hormone, is the most known robust inducer of
CAMP expression in humans, herein we studied the regu-
latory actions of this compound upon CAMP expression in
vitro and in vivo in different types of breast cancer cells.
Our in vitro results showed that calcitriol, at clinically
achievable concentrations, was able to significantly stimu-
late CAMP gene expression in a cell-type specific manner.
Indeed, pharmacological phase I clinical studies involving
subjects affected with cancer have demonstrated that
therapeutic calcitriol may reach peak blood levels of 3–16
nM [22, 23] and herein, with the exception of the cell line
SUM-229PE, the EC50 of calcitriol upon CAMP gene ex-
pression values ranged between 2.13 and 17.1 nM. The fact
that in SUM-229PE cells the EC50 value was very high
might be related to the observation that in this cell line cal-
citriol showed the highest potency to stimulate CYP24A1,
the enzyme that inactivates calcitriol, which most probably
resulted in lesser bioavailability of calcitriol in these cells.
Whereas calcitriol potency was apparently not related
to the cell phenotype, this secosteroid clearly showed a
greater efficacy to increase CAMP gene expression in
ERα- cells. In fact, in HCC1937, HCC1806 and SUM-
229PE cells calcitriol increased CAMP gene expression
from 70 folds to more than 200 folds over control, in
clear contrast with ERα + cells where this stimulus was
less than 10 folds over control. These results suggest
that ERα- breast tumors are more likely to produce
greater amounts of CAMP in response to therapeutic
calcitriol, compared to ERα + tumors. Nevertheless, it
should be noted that cells with higher basal CAMP
gene expression were in fact ERα+, which might prob-
ably indicate that in this cell phenotype a steady state
in CAMP gene expression has already been reached.
On the other hand, in the in vivo model used herein
ERα + cells did not readily formed tumors, probably
due to the lack of estrogen supplementations to mice.
Of the tumorigenic cell lines, triple negative tumors
from the highly undifferentiated HCC1806 cells expressed
significantly more CAMP in response to calcitriol com-
pared to IDC tumors, in accordance to the potency of cal-
citriol upon CAMP gene expression observed in vitro.
Table 2 Stimulation of CYP24A1 gene expression by calcitriol
Cell line Mean ± SD (folds over control)
HCC1937 5.69 ± 0.94
IDC 47.1 ± 18.9
BT-474 83.23 ± 18.01
MCF7 220.42 ± 60.81
HCC1806 7579 ± 1711
SUM-229PE 31181 ± 6192
Depicted cell lines were incubated with 10 nM calcitriol during 24 h and
afterwards RNA was extracted and qPCR performed. Control was normalized
to one, results are expressed as fold induction over control
Fig. 1 Basal CAMP gene expression. Basal CAMP gene expression
was evaluated in several breast cancer cell lines with different
phenotype. Data are depicted as the mean ± SD. N = 3. Results
were normalized against ACTB mRNA expression
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Probably, the time and dose used herein to treat mice with
calcitriol might account on the lack of statistical signifi-
cance found upon tumor volume in this study.
Regarding CAMP biological actions in tumoral cells, it
is noteworthy to mention that CAMP expression has been
closely correlated to HER2 [14] and has been shown to
transactivate EGFR [24, 25], which may explain why can-
cer cells exposed to the CAMP active peptide LL-37 show
increased cell proliferation and invasion [8]. Similarly, in
animal models CAMP treatment promoted tumor growth
and metastasis [14]. Nevertheless, the fact that the highest
CAMP levels have been found in breast tumors of greater
malignancy grade [5], together with the observation of
increased CAMP expression in blood of breast cancer pa-
tients compared to healthy women [26], strongly encour-
ages to explore the biological actions of CAMP in breast
tumor progression. In this regard, binding of LL-37 to
type I insulin-like growth factor receptor in different types
of breast cancer cells has resulted in intra-cellular signal-
ing activation and increased migratory and invasive po-
tential of malignant cells [10]. While additional studies
of CAMP effects on breast cancer biology await to be
undertaken, the calcitriol-mediated induction of CAMP
Fig. 2 CAMP is transcriptionally upregulated by calcitriol in different human breast cancer cell lines. Cells were incubated in the presence of different
calcitriol concentrations during 24 h. Afterwards cells were processed for qPCR. CAMP mRNA levels were obtained by normalizing against ACTB mRNA
expression. Vehicle values were set to one. N = 3, *P < 0.05 vs. control
Table 3 Stimulatory concentrations (EC)50 values for calcitriol
upon CAMP gene expression in breast cancer cells







The effect of calcitriol upon stimulation of cathelicidin gene expression was
evaluated in different types of breast cancer cells
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gene in cancerous tissues has been shown in B-cell
lymphomas, acute myeloid leukemia, colon, prostate,
endometrial and ovarian cancer cell lines [27–31]. Of
particular interest is the observation that in early pre-
malignant and fully malignant breast cells a similar stimu-
latory effect of a calcitriol analogue upon CAMP gene
expression has been observed [32]. However, to our know-
ledge this is the first study to show a differential CAMP
gene expression profile after calcitriol stimulation depend-
ing of the cell type phenotype. Given that calcitriol is an
antineoplastic drug under intense investigation for thera-
peutic purposes, the results in this study may help to
translate calcitriol therapy into the clinic. Since CAMP
may regulate tumorigenesis and/or cell proliferation, more
studies are needed in order to clarify exogenous calcitriol-
dependent CAMP synthesis and biological actions in
breast tumors with different phenotype.
Conclusions
Breast cancer cells showed differential basal CAMP gene
expression depending on the cell phenotype: ERα + breast
cancer cells showed the highest while ERα- the lowest.
Independently of the cell phenotype, calcitriol provoked a
concentration-dependent stimulation on CAMP gene ex-
pression, showing greater potency in the triple negative
HCC1806 cell line. Efficacy of calcitriol was lower in
ERα + cells when compared to ERα- cells in terms of
stimulating CAMP gene expression. Lower basal CAMP
and lack of ERα gene expression were related to in-
creased tumorigenicity. Our results suggest that calci-
triol anti-cancer therapy is more likely to induce higher
levels of CAMP in ERα- breast cancer cells when com-
pared to ERα + breast cancer cells.
Abbreviations
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